Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation

A comparison of our data with that of the phase III trials KEYNOTE-189 and FLAURA suggests that the improved outcomes are due to the use of CPIs or osimertinib. The clinical trial results are well translated into real-world clinical practice with comparable OS. <i>KRAS</i> patients benefit from CPI treatment like no-mutation patients.

Authors

Harald Seifarth
Petros Christopoulos (ORCID: https://orcid.org/0000-0002-7966-8980)
Martin Faehling (ORCID: https://orcid.org/0000-0002-2439-7538)
B. Schwenk
Sabine Fallscheer
Jörn Sträter (ORCID: https://orcid.org/0000-0002-0752-7169)
Claudia Lengerke (ORCID: https://orcid.org/0000-0001-5442-2805)

Institutions

Heidelberg University (DE)
University of Münster (DE)
University Hospital Heidelberg (DE)
National Center for Tumor Diseases (DE)
Klinikum Esslingen (DE)
University of Tübingen (DE)

Publication Details

Journal: Cancers
Published: 2025-04-05
DOI: https://doi.org/10.3390/cancers17071237
Citations: 1
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 1.52

Funders

Deutschen Konsortium für Translationale Krebsforschung

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation

Harald Seifarth, Petros Christopoulos, Martin Faehling, B. Schwenk et al.

Apr 5, 2025

1 citations

Cancers

Lung Cancer Treatments and Mutations

1.52

article

Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation

Harald Seifarth, Petros Christopoulos, Martin Faehling, B. Schwenk, Sabine Fallscheer, Jörn Sträter, Claudia Lengerke

April 5, 2025article en

1 citations

Abstract

A comparison of our data with that of the phase III trials KEYNOTE-189 and FLAURA suggests that the improved outcomes are due to the use of CPIs or osimertinib. The clinical trial results are well translated into real-world clinical practice with comparable OS. <i>KRAS</i> patients benefit from CPI treatment like no-mutation patients.

CancersVol. 17(7)

Heidelberg University (DE), University of Münster (DE), University Hospital Heidelberg (DE), National Center for Tumor Diseases (DE), Klinikum Esslingen (DE), University of Tübingen (DE)

Deutschen Konsortium für Translationale Krebsforschung

Good health and well-being

Openalex Percentile: Top 20%

Lung Cancer Treatments and Mutations

1.52

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation — Harald Seifarth, Petros Christopoulos, et al. · Cancers (2025) | TGRS Research Map | TGRS